Global Cancer Immunotherapy Market, By Drug Class (Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators, Others), Indication (Lung Cancer Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
The cancer immunotherapy market is expected to witness market growth at a rate of 13.5% in the forecast period of 2022 to 2029. Data Bridge Market Research report on cancer immunotherapy market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the prevalence of heart disorder globally is escalating the growth of cancer immunotherapy market.
Cancer immunotherapy refers to a cancer treatment that assists in improving the immune system's ability to fight cancer. This form of therapy is more preferable than the old technique as it offers long-term cancer protection, treats a wider range of cancer and has less side effects. This therapy is utilized in various types of cancers such as prostate cancer, colorectal cancer, head & neck cancer, melanoma, breast cancer, and lung cancer, among others.
The increase in the prevalence of cancer across the globe acts as one of the major factors driving the growth of cancer immunotherapy market. The rise in the adoption of advanced cancer therapeutic options and development of bioinformatic tools enhancing drug development process accelerate the market growth. The introduction of newer drug classes, such as monoclonal antibodies and histone deacetylase (HDAC) inhibitors, that are specifically designed to target receptors related to multiple myeloma further influence the market. Additionally, development in technology, rise in population, surge in healthcare expenditure and growing awareness positively affect the cancer immunotherapy market. Furthermore, increase in clinical trials against several types of cancers in immunotherapy extend profitable opportunities to the market players in the forecast period of 2022 to 2029.
On the other hand, high cost associated with the treatment and availability of limited funds to initiate clinical trials are expected to obstruct the market growth. Complexity of cancer limiting the immune response is projected to challenge the cancer immunotherapy market in the forecast period of 2022-2029.
This cancer immunotherapy market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info cancer immunotherapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Cancer Immunotherapy Market Scope and Market Size
The cancer immunotherapy market is segmented on the basis of drug class, indication, route of administration, distribution channel and end-users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of drugs class, the cancer immunotherapy market is segmented into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, immunomodulators and others.
- On the basis of indication, the cancer immunotherapy market is segmented into lung cancer breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer and others.
- On the basis of route of administration, the cancer immunotherapy market is segmented into oral, inhalation, intravenous and others.
- On the basis of distribution channel, the cancer immunotherapy market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
- On the basis of end-users, the cancer immunotherapy market is segmented into hospitals, homecare, specialty clinics and others.
Cancer Immunotherapy Market Country Level Analysis
The cancer immunotherapy market is analyzed and market size information is provided by country, drug class, indication, route of administration, distribution channel and end-users as referenced above.
The countries covered in the global cancer immunotherapy market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the cancer immunotherapy market due to the developed healthcare infrastructure within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2021 to 2028 because of the large population in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The cancer immunotherapy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Cancer Immunotherapy Market Share Analysis
The cancer immunotherapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related cancer immunotherapy market.
Some of the major players operating in the cancer immunotherapy market report are F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd, Bayer AG, Fresenius Kabi AG, Dr. Reddy’s Laboratories Ltd., Bausch Health, LUPIN, AstraZeneca, Teva Pharmaceutical Industries Ltd, Mylan N.V., Hikma Pharmaceutical Plc, Apotex Inc, Immunomedics Inc, Amneal Pharmaceutical Inc, Merck & Co., Inc., and Aspen Holdings, among others.